NeoDynamics AB (publ) announced that the Company has been granted a Chinese patent for the needle design employed in the NeoNavia FlexiPulse probe. The front-loaded, open-tip sampling needle is designed to enable maximum tissue yield, with minimal patient trauma. The patent is an important milestone that opens up for a future commercial launch in China and strengthens the protection of the NeoNavia biopsy system.

NeoNavia with FlexiPulse is uniquely positioned to address biopsies in the axillary lymph nodes which is a technically and anatomically challenging site due to the proximity to blood vessels anderves. The Chinese patent is yet another important milestone that comes on top of a similar patent granted in the US in August 2021, followed by US FDA clearance received in September 2022.